Nordic Bone
ABOUT USINVESTORSPIPELINENEWSCONTACTACCOUNTSDIVIDENDEGM & AGM NOTICE

Partnering

Osteologix has a competitive intellectual property position and is looking for collaboration and partnership in further clinical areas to maximize commercial exploitation of its comprehensive patent portfolio. Osteologix focuses its internal development effort on its candidate drug programs in the areas of metabolic bone diseases and arthritis.

Osteologix has entered into a licence agreement with Les Laboratoires Servier to develop and commercialise NBS101 worldwide except in the USA (see Press Release of August 2nd, 2010.) The company continues to seek a suitable development and commercialisation partner for the USA.